extract: 2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -17,6 +17,12 @@ But the economics are structurally inflationary. Meta-analyses show patients reg
 
 The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive prices down, but volume growth more than offsets price compression. GLP-1s will be the single largest driver of pharmaceutical spending growth globally through 2035.
 
+
+### Additional Evidence (extend)
+*Source: [[2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations]] | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
+
+Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -0,0 +1,58 @@
+---
+type: claim
+domain: health
+description: "Two-year real-world data shows only 15% of non-diabetic obesity patients remain on GLP-1s, meaning most patients discontinue before downstream health benefits can materialize to offset drug costs"
+confidence: likely
+source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
+created: 2026-03-11
+depends_on: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
+---
+
+# GLP-1 persistence drops to 15 percent at two years for non-diabetic obesity patients undermining chronic use economics
+
+Real-world claims data from 125,474 commercially insured patients initiating GLP-1 receptor agonists for obesity (without type 2 diabetes) reveals a persistence curve that fundamentally challenges the economic model: 46.3% remain on treatment at 180 days, 32.3% at one year, and approximately 15% at two years.
+
+This creates a paradox for payer economics. The "chronic use inflation" concern assumes patients stay on GLP-1s indefinitely at $2,940+ annually. But the actual problem may be insufficient persistence: under capitation, a Medicare Advantage plan pays for 12 months of GLP-1 therapy for a patient who discontinues and regains weight—net cost with no downstream savings from avoided complications.
+
+The economics only work if adherence is sustained AND the payer captures downstream benefits. With 85% of non-diabetic patients discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients.
+
+## Evidence
+
+**Persistence rates for non-diabetic obesity patients:**
+- 180 days: 46.3%
+- 1 year: 32.3%
+- 2 years: ~15%
+
+**Comparison with diabetic patients:**
+- Non-diabetic patients: 67.7% discontinue within 1 year
+- Diabetic patients: 46.5% discontinue within 1 year (better persistence due to stronger clinical indication)
+- Danish registry data: 21.2% of T2D patients discontinue within 12 months; ~70% discontinue within 2 years
+
+**Drug-specific variation:**
+- Semaglutide: 47.1% persistence at 1 year (highest)
+- Liraglutide: 19.2% persistence at 1 year (lowest)
+- Formulation matters: oral formulations may improve adherence by removing injection barrier
+
+**Key discontinuation factors:**
+- Insufficient weight loss (clinical disappointment)
+- Income level (lower income → higher discontinuation, suggesting affordability/access barriers)
+- Adverse events (primarily GI side effects)
+- Insurance coverage changes
+
+**Critical nuance from source:** "Outcomes approach trial-level results when focusing on highly adherent patients. The adherence problem is not that the drugs don't work—it's that most patients don't stay on them."
+
+## Challenges
+
+This data comes from commercially insured populations (younger, fewer comorbidities than Medicare). Medicare populations may show different persistence patterns due to higher disease burden and stronger clinical indications. However, Medicare patients also face higher cost-sharing barriers, which could worsen adherence.
+
+No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
+
+---
+
+Relevant Notes:
+- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
+- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
+
+Topics:
+- domains/health/_map

domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md

@@ -0,0 +1,48 @@
+---
+type: claim
+domain: health
+description: "Income level correlates with GLP-1 discontinuation rates in commercially insured populations, indicating that cost-sharing and affordability barriers drive adherence as much as clinical factors like side effects or insufficient weight loss"
+confidence: experimental
+source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
+created: 2026-03-11
+---
+
+# Lower-income patients show higher GLP-1 discontinuation rates suggesting affordability not just clinical factors drive persistence
+
+Among the factors associated with GLP-1 discontinuation in commercially insured populations, income level emerges as a significant predictor: lower-income patients show higher discontinuation rates even when controlling for other factors.
+
+This is notable because the study population is commercially insured—meaning all patients have coverage. The income effect suggests that cost-sharing (copays, deductibles) creates an affordability barrier even within insured populations. For Medicare populations with higher cost-sharing and lower average incomes, this barrier may be substantially worse.
+
+The implication for value-based care design: reducing patient cost-sharing for GLP-1s (through zero-copay programs or coverage carve-outs) may improve persistence enough to make the downstream ROI positive. The relevant question is not "does the drug work?" but "can patients afford to stay on it long enough for it to work?"
+
+## Evidence
+
+**Key discontinuation factors identified:**
+- Insufficient weight loss (clinical disappointment)
+- **Income level (lower income → higher discontinuation)**
+- Adverse events (GI side effects)
+- Insurance coverage changes
+
+The source notes income as a factor but does not provide the specific discontinuation rate by income quartile. This limits the strength of the claim to experimental confidence.
+
+**Context:**
+- Study population: commercially insured adults (younger, higher income than Medicare)
+- Even within this relatively advantaged population, income predicts discontinuation
+- Medicare populations face higher cost-sharing (Part D coverage gap, higher average out-of-pocket costs)
+
+**Mechanism hypothesis:**
+At $245/month list price, even modest copays ($50-100/month) create a sustained affordability barrier. Patients may initiate treatment but discontinue when the monthly cost becomes unsustainable relative to household budget.
+
+## Challenges
+
+The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se.
+
+---
+
+Relevant Notes:
+- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
+- [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]
+
+Topics:
+- domains/health/_map

domains/health/semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x.md

@@ -0,0 +1,40 @@
+---
+type: claim
+domain: health
+description: "Within the GLP-1 class, semaglutide shows 2.5x better one-year persistence than liraglutide (47.1% vs 19.2%), suggesting formulation and dosing frequency significantly impact real-world adherence independent of efficacy"
+confidence: likely
+source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
+created: 2026-03-11
+---
+
+# Semaglutide achieves 47 percent one-year persistence versus 19 percent for liraglutide showing drug-specific adherence variation of 2.5x
+
+Within the GLP-1 receptor agonist class, drug-specific persistence rates vary dramatically: semaglutide maintains 47.1% of non-diabetic obesity patients at one year, while liraglutide retains only 19.2%—a 2.5x difference.
+
+This variation matters because it suggests adherence is not purely about the drug class mechanism or patient characteristics, but about formulation factors: semaglutide's once-weekly injection versus liraglutide's daily injection likely drives much of the difference. Oral formulations (like oral semaglutide) may further improve adherence by removing the injection barrier entirely.
+
+For payer economics and value-based care design, this means drug selection within the GLP-1 class significantly impacts the probability that downstream savings will materialize. A plan that preferentially covers liraglutide for cost reasons may be optimizing for upfront price while guaranteeing that 80% of patients discontinue before benefits accrue.
+
+## Evidence
+
+**One-year persistence rates by drug (non-diabetic obesity patients):**
+- Semaglutide: 47.1%
+- Liraglutide: 19.2%
+- Overall class average: 32.3%
+
+**Likely mechanism:**
+- Semaglutide: once-weekly subcutaneous injection
+- Liraglutide: daily subcutaneous injection
+- Injection frequency is a known adherence barrier across therapeutic classes
+
+**Implications for formulary design:**
+If a payer's goal is to maximize the probability of sustained adherence (and thus downstream ROI), preferencing higher-persistence drugs may justify higher upfront costs. The relevant comparison is not semaglutide cost vs. liraglutide cost, but (semaglutide cost × 47% persistence) vs. (liraglutide cost × 19% persistence).
+
+---
+
+Relevant Notes:
+- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
+
+Topics:
+- domains/health/_map

domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md

@@ -23,6 +23,12 @@ The Making Care Primary model's termination in June 2025 (after just 12 months,
 
 PACE represents the extreme end of value-based care alignment—100% capitation with full financial risk for a nursing-home-eligible population. The ASPE/HHS evaluation shows that even under complete payment alignment, PACE does not reduce total costs but redistributes them (lower Medicare acute costs in early months, higher Medicaid chronic costs overall). This suggests that the 'payment boundary' stall may not be primarily a problem of insufficient risk-bearing. Rather, the economic case for value-based care may rest on quality/preference improvements rather than cost reduction. PACE's 'stall' is not at the payment boundary—it's at the cost-savings promise. The implication: value-based care may require a different success metric (outcome quality, institutionalization avoidance, mortality reduction) than the current cost-reduction narrative assumes.
 
+
+### Additional Evidence (extend)
+*Source: [[2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations]] | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
+
+GLP-1 persistence data illustrates why value-based care requires risk alignment: with only 32.3% of non-diabetic obesity patients remaining on GLP-1s at one year (15% at two years), the downstream savings that justify the upfront drug cost never materialize for 85% of patients. Under fee-for-service, the pharmacy benefit pays the cost but doesn't capture the avoided hospitalizations. Under partial risk (upside-only), providers have no incentive to invest in adherence support because they don't bear the cost of discontinuation. Only under full risk (capitation) does the entity paying for the drug also capture the downstream savings—but only if adherence is sustained. This makes GLP-1 economics a test case for whether value-based care can solve the "who pays vs. who benefits" misalignment.
+
 ---
 
 Relevant Notes:

inbox/archive/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md

@@ -7,9 +7,15 @@ date: 2024-08-01
 domain: health
 secondary_domains: []
 format: paper
-status: unprocessed
+status: processed
 priority: high
 tags: [glp-1, adherence, persistence, discontinuation, real-world-evidence, obesity]
+processed_by: vida
+processed_date: 2026-03-11
+claims_extracted: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Three new claims extracted focusing on the persistence paradox (chronic use economics fail because of insufficient adherence, not excessive adherence), drug-specific variation (semaglutide 2.5x better than liraglutide), and income-driven discontinuation (affordability barrier even in commercially insured populations). Two enrichments applied to existing GLP-1 and value-based care claims, adding the critical 2-year persistence data (15%) that reframes the economic argument. The curator note was correct: this source reframes the 'chronic use inflation' concern—the actual problem is that most patients don't stay on long enough for downstream benefits to materialize."
 ---
 
 ## Content
@@ -49,3 +55,11 @@ Real-world claims study of 125,474 patients initiating GLP-1 RAs for obesity (wi
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: The persistence data reframes the economic argument — the "chronic use" problem may actually be an "insufficient persistence" problem. Most patients don't stay on long enough for downstream benefits to materialize.
 EXTRACTION HINT: Focus on the paradox: chronic use makes GLP-1s expensive, but discontinuation eliminates the downstream savings that justify the cost. The economics only work if adherence is sustained AND the payer captures downstream savings.
+
+
+## Key Facts
+- Study analyzed 125,474 commercially insured patients initiating GLP-1 RAs for obesity without type 2 diabetes
+- Overall GLP-1 persistence: 46.3% at 180 days, 32.3% at 1 year, ~15% at 2 years
+- Diabetic patients show better persistence: 53.5% at 1 year vs. 32.3% for non-diabetic
+- Danish registry comparison: 21.2% of T2D patients discontinue within 12 months; ~70% discontinue within 2 years
+- Key discontinuation factors: insufficient weight loss, income level, adverse events (GI), insurance coverage changes